Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet; Roser Pinyol; Robin K. Kelley; Anthony El-Khoueiry; Helen L. Reeves; Xin Wei Wang; Gregory J. Gores; Augusto Villanueva

doi:10.1038/s43018-022-00357-2

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet, Roser Pinyol, Robin K. Kelley, Anthony El-Khoueiry, Helen L. Reeves, Xin Wei Wang, Gregory J. Gores, Augusto Villanueva

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

Abstract

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.

Original language	English (US)
Pages (from-to)	386-401
Number of pages	16
Journal	Nature Cancer
Volume	3
Issue number	4
DOIs	https://doi.org/10.1038/s43018-022-00357-2
State	Published - Apr 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-022-00357-2

Cite this

@article{ce12f97433a84d9c9ff2e85c2bb4b967,

title = "Molecular pathogenesis and systemic therapies for hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.",

author = "Llovet, {Josep M.} and Roser Pinyol and Kelley, {Robin K.} and Anthony El-Khoueiry and Reeves, {Helen L.} and Wang, {Xin Wei} and Gores, {Gregory J.} and Augusto Villanueva",

note = "Publisher Copyright: {\textcopyright} 2022, Springer Nature America, Inc.",

year = "2022",

month = apr,

doi = "10.1038/s43018-022-00357-2",

language = "English (US)",

volume = "3",

pages = "386--401",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "4",

}

TY - JOUR

T1 - Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

AU - Llovet, Josep M.

AU - Pinyol, Roser

AU - Kelley, Robin K.

AU - El-Khoueiry, Anthony

AU - Reeves, Helen L.

AU - Wang, Xin Wei

AU - Gores, Gregory J.

AU - Villanueva, Augusto

PY - 2022/4

Y1 - 2022/4

N2 - Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.

AB - Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85128907027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128907027&partnerID=8YFLogxK

U2 - 10.1038/s43018-022-00357-2

DO - 10.1038/s43018-022-00357-2

M3 - Review article

C2 - 35484418

AN - SCOPUS:85128907027

SN - 2662-1347

VL - 3

SP - 386

EP - 401

JO - Nature Cancer

JF - Nature Cancer

IS - 4

ER -

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this